Total-body PET scan maps HER2 tracer in breast cancer and finds earlier imaging window
A dynamic total-body PET/CT study of Ga-HER2 Affibody in HER2-positive breast cancer patients measured organ biodistribution, an effective dose of ...
A dynamic total-body PET/CT study of Ga-HER2 Affibody in HER2-positive breast cancer patients measured organ biodistribution, an effective dose of ...
Researchers built a single automated cassette workflow that produces, purifies and radiolabels zirconium-89 DFO-trastuzumab, achieving 100% radiochemical purity by HPLC ...
A survey of 74 patients with HER2-positive breast cancer in Australia and the United States found 74.3% were likely to ...
A retrospective Indian analysis of 101 patients reports real-world efficacy and safety outcomes for the trastuzumab emtansine biosimilar UJVIRA in ...
A seven-year follow-up of the PROTECT HER2 trial found that prophylactic carvedilol offered no significant long-term cardiovascular benefit in early-stage ...
A single-center study of 21 patients found that trastuzumab emtansine produced no responses and a median progression-free survival of 2.20 ...
A published case report describes curative breast tumour removal performed during combined ECMO and Impella support in a woman who ...
A multicenter Chinese real-world cohort found that adjuvant T-DM1 was associated with better early invasive disease-free survival than trastuzumab plus ...
An analysis of 81 Ethiopian breast cancer tissue samples associated higher immune-cell and PD-L1 measures with non-luminal subtypes and grade ...
A retrospective cohort of 450 East Asian patients with HER2-positive breast cancer found that subcutaneous neoadjuvant trastuzumab was associated with ...
The Alliance for Clinical Trials in Oncology marks Breast Cancer Awareness Month with eight active trials spanning treatment de-escalation, survivorship ...
A prospective study finds that 68Ga-HER2 PET/CT scans after just two cycles of neoadjuvant therapy can predict which HER2-positive breast ...
A multicenter phase II trial found that a pyrotinib-based neoadjuvant regimen achieved pathological response rates comparable to the standard trastuzumab-pertuzumab ...
A new Nature Reviews Clinical Oncology review charts how HER2-targeted therapies, led by trastuzumab deruxtecan, are driving a shift from ...
A rough set theory analysis of the METABRIC cohort shows that a compact set of routine clinical variables can moderately ...
Secondary results from the ECOG-ACRIN CompassHER2-pCR trial identify clinical and molecular factors, including HER2DX genomic scores, that predict which stage ...
In a groundbreaking study poised to reshape therapeutic strategies for early-stage HER2-positive breast cancer, researchers have delved deep into the ...
On the forefront of cancer research, a groundbreaking study has emerged, shedding light on how to enhance the efficacy of ...
In recent groundbreaking research, the significance of trastuzumab emtansine (T-DM1) has taken center stage in the battle against high-risk HER2-positive ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.